TY  - JOUR
AU  - Perović, Bojana
AU  - Jovanović, Marija
AU  - Miljković, Branislava
AU  - Vezmar, Sandra
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1392
AB  - Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.
PB  - Dove Medical Press Ltd, Albany
T2  - Neuropsychiatric Disease and Treatment
T1  - Getting the balance right: Established and emerging therapies for major depressive disorders
VL  - 6
SP  - 343
EP  - 364
DO  - 10.2147/NDT.S10485
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1392
ER  - 

@article{
author = "Perović, Bojana and Jovanović, Marija and Miljković, Branislava and Vezmar, Sandra",
year = "2010",
abstract = "Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.",
publisher = "Dove Medical Press Ltd, Albany",
journal = "Neuropsychiatric Disease and Treatment",
title = "Getting the balance right: Established and emerging therapies for major depressive disorders",
volume = "6",
pages = "343-364",
doi = "10.2147/NDT.S10485",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1392"
}

Perović, B., Jovanović, M., Miljković, B.,& Vezmar, S.. (2010). Getting the balance right: Established and emerging therapies for major depressive disorders. in Neuropsychiatric Disease and Treatment
Dove Medical Press Ltd, Albany., 6, 343-364.
https://doi.org/10.2147/NDT.S10485
https://hdl.handle.net/21.15107/rcub_farfar_1392

Perović B, Jovanović M, Miljković B, Vezmar S. Getting the balance right: Established and emerging therapies for major depressive disorders. in Neuropsychiatric Disease and Treatment. 2010;6:343-364.
doi:10.2147/NDT.S10485
https://hdl.handle.net/21.15107/rcub_farfar_1392 .

Perović, Bojana, Jovanović, Marija, Miljković, Branislava, Vezmar, Sandra, "Getting the balance right: Established and emerging therapies for major depressive disorders" in Neuropsychiatric Disease and Treatment, 6 (2010):343-364,
https://doi.org/10.2147/NDT.S10485 .,
https://hdl.handle.net/21.15107/rcub_farfar_1392 .